Novo post hoc analysis finds Wegovy® 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m², presented at The Liver Meeting® (AASLD) 2026

Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026

Financial report for the period 1 January 2026 to 30 September 2026